How 23andMe Went From $6B Valuation to Penny Stock
How 23andMe Went From $6B Valuation to Penny Stock
DNA-testing company 23AndMe and its founder, Anne Wojcicki, aimed to revolutionize healthcare, bringing genetic tests to homes with just a tube of spit.

But challenges with its business model and continued data privacy concerns for consumers have brought the company once valued at $6 billion to a valuation of nearly $0, with Nasdaq threatening to delist it. 

WSJ explains what went wrong with Wojcicki’s biotech business. 

  • 0:00 Home DNA testing
  • 0:49 The rise of 23andMe
  • 2:18 The turning point
  • 4:03 23andMe’s fall
  • 5:23 What’s next?

What Went Wrong explores the challenging conditions and decisions that led to a company's downturn.

What's your reaction?


0 comment

Write the first comment for this!

Facebook Conversations